APA (7th ed.) Citation

Batran, S. a., Hofheinz, R., Haag, G. M., Heike, M., Ronellenfitsch, U., Gaiser, T., . . . Mönig, S. P. (2016). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The lancet. Oncology, 17(12), . https://doi.org/10.1016/S1470-2045(16)30531-9

Chicago Style (17th ed.) Citation

Batran, Salah-Eddin al-, Ralf-Dieter Hofheinz, Georg Martin Haag, Michael Heike, Ulrich Ronellenfitsch, Timo Gaiser, Peter Schirmacher, Mark Sievert, and Stefan Paul Mönig. "Histopathological Regression After Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin Versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-label, Randomised Phase 2/3 Trial." The Lancet. Oncology 17, no. 12 (2016). https://doi.org/10.1016/S1470-2045(16)30531-9.

MLA (9th ed.) Citation

Batran, Salah-Eddin al-, et al. "Histopathological Regression After Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin Versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients with Resectable Gastric or Gastro-oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results from the Phase 2 Part of a Multicentre, Open-label, Randomised Phase 2/3 Trial." The Lancet. Oncology, vol. 17, no. 12, 2016, https://doi.org/10.1016/S1470-2045(16)30531-9.